BioPartners GmbH Receives EU Marketing Authorization for Ribavirin Biopartners 200mg Film-Coated Tablets for Chronic Hepatitis C
4/8/2010 11:49:30 AM
BAAR, Switzerland--(BUSINESS WIRE)--Biopartners GmbH has announced that it has received EU marketing authorization from the European Commission for Ribavirin Biopartners 200mg film-coated tablets. The product is intended for the treatment of chronic hepatitis C infection as part of a combination regimen with peginterferon alfa-2b or interferon alfa-2b.
comments powered by